Zulresso Is Sage’s First Step In Postpartum Depression Treatment
I.V. Zulresso is the first US FDA-approved drug for postpartum depression (PPD) and Sage's first commercial product – with a list price of $34,000. It will help the company build a presence in PPD as it completes late-stage development for oral candidate SAGE-217.
You may also be interested in...
The company updated investors on the launch of the first treatment for postpartum depression during its Q2 earnings call. More than 100 sites have been certified under the REMS.
First quarter biopharma financing, at $17.96bn, demonstrated a 65% increase over Q4 2018. The $92bn in total M&A activity was led by Bristol-Myers Squibb's $74bn buy of top-tier public biotech Celgene. At $39.4bn in total potential deal value, alliance dealmaking started off 2019 strong, with most of the top partnerships in modalities outside the recently popular areas of immune checkpoint inhibitors or CAR-T therapies.